Navigation Links
Novartis Drug Afinitor® Effective in Patients With Non-Cancerous Kidney Tumors Associated With TSC in Phase III Trial
Date:9/23/2011

hieved net sales of USD 50.6 billion, while approximately USD 9.1 billion (USD 8.1 billion excluding impairment and amortization charges) was invested in R&D throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 121,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.us.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis.

*Known as Votubia® (everolimus) tablets for certain patients with SEGA associated with TSC in the EU and Switzerland.

# Rapamune® (sirolimus) and Torisel® (temsirolimus) are registered trademarks of Wyeth Pharmaceuticals Inc.

References

  1. Kingswood et al. A randomized, double-blind, placebo-controlled, phase 3 study of everolimus in the treatment of angiomyolipoma in patients with either tuberous sclerosis complex or sporadic lymphangioleiomyomatosis. International TSC Research Conference. September 2011, Belfast, Northern Ireland.
  2. Ewalt, et al. Long-term outcome of transcatheter embolization of renal angiomyolipomas due to Tuberous Sclerosis Complex. J Urol 2005:174:1764-1766.
  3. National Institute of Neurological Disorders and Stroke. Tuberous Sclerosis Fact Sheet. Available at http://www.ninds.nih.gov/disorders/tuberous_sclerosis/detail_tuberous_sclerosis.htm. Accessed September 2011.
  4. Roach, et al. Diagnosis of Tuberous Sclerosis Complex. J Child Neuro 2004;19:643-649.
  5. Franz, et al. Long-term safety and efficacy results of oral everolimus in patients with subependymal giant cell astrocytomas (SEGA) in tuberous sclerosis complex (TSC). International TSC Research Conferen
    '/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Novartis Study Showed ACZ885 Provided Substantial Symptom Relief in 84% of Patients With the Most Serious Form of Childhood Arthritis
2. Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
3. Novartis Drug Gleevec® Shows Significant Overall Survival Benefit for Patients With GIST After Three Years of Adjuvant Treatment vs. One Year
4. Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis
5. Novartis Data Shows ACZ885 for Severe Gouty Arthritis Provided Better Pain Relief and Reduced Risk of New Attacks by Up to 68% vs. Steroid
6. FDA Approves Novartis Drug Afinitor to Treat Pancreatic Neuroendocrine Tumors
7. Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET
8. Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin
9. US Supreme Court Denies Certiorari and Thereby Leaves in Place Second Circuit Ruling That Novartis Pharmaceuticals Corporation Must Pay its Sales Representatives Overtime Compensation
10. Novartis Gains FDA Approval for Amturnide™, a Triple-Combination Pill to Treat High Blood Pressure in Patients Uncontrolled on Two Medications
11. Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... South Africa , Jan. 23, 2015   Leatt ... of personal protective equipment for all forms of sports, ... flagship Leatt-Brace® neck brace, announced today that the UISP ... federation, now requires all riders to wear a neck ...
(Date:1/23/2015)... China , Jan. 23, 2015 Tianyin Pharmaceutical ... company that specializes in the development and sale of ... generics and active pharmaceutical ingredients (API) today announced the ... (JCM) API operation. 1. Following the September ...
(Date:1/22/2015)... 22, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or ... Omega-3 therapies for cardiovascular disease and overall health is pleased ... in 2014 and its outlook for 2015 from the CEO, ... We would like to take this opportunity to ...
Breaking Medicine Technology:Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 3TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7
... Sandwich" Device is First to Mimic Natural Physical Environment, ... challenges to islet,cell transplantation as the treatment of choice ... supply. Patients often need a re-infusion of islet,cells after ... is,needed to provide the fragile islet cells for transplant. ...
... In Patients With BPH, Clinical Benefit After Ozarelix Was Maintained For ... ... Commence Before Year End Or Soon Thereafter, IRVINE, Calif., Sept. 5 ... and efficacy data for ozarelix, the Company,s drug candidate for the,treatment of ...
Cached Medicine Technology:Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells 2Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale d'Urologie 2Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale d'Urologie 3Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale d'Urologie 4Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale d'Urologie 5
(Date:1/22/2015)... Angelweddingdress is a famous wedding dress company ... to follow it on Facebook, Twitter, and Pinterest. The fans ... Angelweddingdress draws a lottery every week. , Moreover, the company ... 2015. Click Angelweddingdress homepage for more information. ...
(Date:1/22/2015)... January 23, 2015 AngelWeddingDress, the premier ... 2015 maternity wedding dresses. View website of ... looking for maternity wedding dresses online for a bridal ... with high quality for them. Its maternity wedding dresses ...
(Date:1/22/2015)... Juvent Sports ( http://www.juventsports.com ) and ... Merchandise Show to bestow a Juvent Sports Achievement award ... Arlene McKitrick. The award commemorated and congratulated McKitrick for ... She won her first amateur tournament in 1979 and ...
(Date:1/22/2015)... January 22, 2015 Thousand of GranuFlo ... Care recalled its GranuFlo and NaturaLyte dialysis concentrates continue ... in U.S. District Court, District of Massachusetts, Bernstein Liebhard ... the Court has remanded a case filed by the ...
(Date:1/22/2015)... over 20 years, Dr. David Cruz of Cruz Chiropractic Care ... just about every type of injury that can result from car ... twenty-plus years, the team at Doctors on Liens has ... doctor. With the combined breadth of experience between the ...
Breaking Medicine News(10 mins):Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2
... JOSE, Calif., May 22 VNUS(R) Medical,Technologies, Inc. (Nasdaq: ... the minimally invasive treatment of venous reflux disease, today,announced ... 12th Annual,Spring Investor Conference, to be held May 28-29, ... NY., VNUS, presentation is currently scheduled for 12:50 ...
... DURHAM, N.C. -- A new study by Duke University researchers provides ... of a cell plays a key role in disease, and the ... heart disease and cancer. , The nitric oxide system in cells ... regard to the way it controls proteins, and it is linked ...
... HHS Secretary Mike,Leavitt today announced efforts underway ... the Centers for Medicare & Medicaid Services (CMS),that ... and the quality,of medical care., "This initiative ... use of medical products on the market," Secretary ...
... study suggests threat of starvation triggers the switch , , ... suggests the body,s biological clock, which regulates sleep cycles ... can be overridden in extreme situations by an internal ... with mice and has not yet been tested among ...
... For patients undergoing kidney transplantation, treatment with the anti-rejection ... diabetes, reports a study in the July Journal of ... a robust association between sirolimus and diabetes after transplantation ... the United States," comments Dr. John S. Gill of ...
... (Amex:,ADL), ( http://www.amdl.com ), a world leader ... Jilin, China, announced today that,it has made available ... financial results conference call. The document can be ... Click on "Investor Relations",then "Recent News.", The ...
Cached Medicine News:Health News:Major 'missed' biochemical pathway emerges as important in virtually all cells 2Health News:Major 'missed' biochemical pathway emerges as important in virtually all cells 3Health News:New Efforts to Help Improve Medical Products for Patient Safety and Quality of Medical Care 2Health News:New Efforts to Help Improve Medical Products for Patient Safety and Quality of Medical Care 3Health News:New Efforts to Help Improve Medical Products for Patient Safety and Quality of Medical Care 4Health News:'Food Clock' May Override Master Sleep Clock in Times of Duress 2Health News:'Food Clock' May Override Master Sleep Clock in Times of Duress 3Health News:'Food Clock' May Override Master Sleep Clock in Times of Duress 4Health News:Anti-rejection drug may increase risk of diabetes after kidney transplant 2Health News:AMDL Teleconference Available on amdl.com at 5:00 p.m. EDT Today 2
... an average 5:1 increase in usage time at ... a standard cannula. , ,The combination of ... oxygen patients a superior alternative to liquid oxygen. ... , ,NOTE: Each ...
... An All-In-One Conserver., ,Offers an average 5:1 ... ,Allows the use of a standard cannula. ... and lightweight cylinders offers ambulatory oxygen patients a ... backed by a 2-year warranty. ...
Redesigning the World's Oxygen Therapy One Device at a Time. , ,Everything you like about our OXYMATIC 400 Series conservers, only better!...
... Conservation Device. Bypass 6200: Direct ... Accessories: , OCD870C CGA 870 ... Regulator , OCD2001-18 Carrying Pouch ... CP2140 Vertical M-6 Cylinder Carrying ...
Medicine Products: